VLBW Hospitalized Infants Face High S aureus Infection Risk
METHODOLOGY:
Researchers conducted a retrospective cohort study to determine the incidence of invasive S aureus infections among 468,201 infants (55.6% boys; median gestational age, 36 weeks) admitted to NICUs across the United States between 2016 and 2021.
infections among 468,201 infants (55.6% boys; median gestational age, 36 weeks) admitted to NICUs across the United States between 2016 and 2021. The primary outcome was late-onset invasive S aureus infection, defined as a positive culture result for S aureus from an abscess, blood, cerebrospinal fluid, peritoneum, or pleural fluid, collected at least 4 days after birth.
infection, defined as a positive culture result for from an abscess, blood, cerebrospinal fluid, peritoneum, or pleural fluid, collected at least 4 days after birth. Mortality attributed to S aureus infection was defined as the absolute difference in deaths occurring within 7 days of an invasive S aureus infection and deaths among matched infants without an S aureus infection.
TAKEAWAY:
Among infants with invasive infections, 80.9% were born at 32 weeks of gestation or earlier, 76.5% had VLBW, and 87.5% required central line placement during their NICU stay.
Infants with VLBW experienced nearly a 20-fold higher incidence of S aureus infection rates than infants with a birth weight ≥ 1500 g (227.1; 95% CI, 215.3-239.4 vs 10.1; 95% CI, 9.1-11.1 per 10,000 infants).
infection rates than infants with a birth weight ≥ 1500 g (227.1; 95% CI, 215.3-239.4 vs 10.1; 95% CI, 9.1-11.1 per 10,000 infants). Among infants with S aureus infections, all-cause mortality was substantially higher in infected infants (12.1% vs 1.0%), with VLBW infants accounting for 90.4% of deaths.
infections, all-cause mortality was substantially higher in infected infants (12.1% vs 1.0%), with VLBW infants accounting for 90.4% of deaths. The absolute difference in 7-day all-cause mortality between infants with S aureus infection occurring between postnatal days 4 and 28 and matched infants without infection was 5.3% (95% CI, 3.8-6.8).
IN PRACTICE:
'Late-onset invasive S aureus is an important contributor to disease burden in hospitalized infants, especially among infants with VLBW,' the study authors wrote.
'The lack of change in the incidence mediated by enhanced infection prevention measures suggests the need for novel strategies to further reduce the incidence and burden of S aureus infections,' wrote the study authors of the related editorial.
SOURCE:
The study was led by Aaron M. Milstone, MD, MHS, Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore. It was published online on April 14, 2025, in JAMA Pediatrics .
LIMITATIONS:
The convenience sample may not have been representative of all hospitalized infants in US NICUs. Data were limited to infants during their admission to participating sites, potentially missing infections that occurred before admission or after transfer to another hospital. Additionally, the researchers were unable to explore differences in outcomes between methicillin-resistant and methicillin-sensitive S aureus infections.
DISCLOSURES:
The study received support from the Centers for Disease Control and Prevention and the National Institutes of Health. Three authors reported receiving consulting fees, grants, or honoraria from companies such as Tellus Therapeutics, Oak Hill Bio, Pediatrix, AbbVie, and Thermo Fisher Scientific PPD.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
Ointment Cuts Severe Radiation Mucositis in Nasopharyngeal Cancer
TOPLINE: Bacterial decolonization with mupirocin nasal ointment significantly lowered rates of severe acute radiation oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy. The intervention also reduced oral pain and dysphagia, and improved quality of life (QOL) without increasing radiation dermatitis. METHODOLOGY: Acute radiation oral mucositis is a common, debilitating complication of radiotherapy in patients with nasopharyngeal carcinoma. Research showed that oral Staphylococcus aureus, a potential factor in oral mucositis, can increase after radiotherapy. Mupirocin, an inexpensive topical antibiotic, can help eliminate S aureus from nasal and oral sites but has not been tested in this setting. Researchers conducted a phase 3 trial of 176 patients with nasopharyngeal carcinoma (median age, 52 years) undergoing radiotherapy, who were randomly assigned to receive either a bacterial decolonization regimen with mupirocin nasal ointment (n = 88) or standard of care (n = 88). The decolonization regimen consisted of mupirocin nasal ointment applied twice daily for 5 days, starting 3 days before radiotherapy, followed by a 1-week break; this cycle was repeated throughout treatment. All patients received routine oral care with Kangfuxin Liquid mouth rinses and nasal saline irrigation. The primary endpoint was the occurrence of severe (grade ≥ 3) oral mucositis during radiotherapy. Secondary endpoints were QOL, pain, S aureus colonization in the oral and nasal cavities, and the incidence of grade ≥ 2 radiation dermatitis. TAKEAWAY: Severe oral mucositis occurred in 22.7% of the mupirocin group vs 47.7% of the standard care group (relative risk, 0.48; P < .001). Kaplan-Meier analysis also showed a significantly lower cumulative incidence of severe oral mucositis among patients receiving mupirocin (22.8% vs 48.3%). Bacterial decolonization and the mean oral radiation dose were independent risk factors for severe acute radiation oral mucositis, with decolonization reducing the risk (odds ratio [OR], 0.27) and a higher radiation dose increasing the risk (OR, 3.93). Age (OR, 1.61; P = .16) and S aureus presence (OR, 1.59; P = .19) were not independent risk factors. At week 4, patients in the mupirocin group reported less oral pain (median score, 25.0 vs 50.0) and dysphagia (8.3 vs 33.3), with improvements sustained through treatment completion. The rates of grade ≥ 2 radiation dermatitis did not differ between the groups. By the end of treatment, S aureus colonization was significantly lower in the bacterial decolonization group at both nasal (9.4% vs 22.9%) and oral (5.9% vs 20.5%) sites. IN PRACTICE: 'This phase 3 randomized clinical trial demonstrated that the mupirocin-based BD [bacterial decolonization] therapy effectively reduced AROM [acute radiation oral mucositis] severity and improves QOL in patients with NPC [nasopharyngeal carcinoma] undergoing radiotherapy,' the authors of the study wrote, adding that mupirocin is a 'safe, simple, and cost-effective strategy to reduce AROM severity.' SOURCE: This study, led by Zhaohui Liao, BSN, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College in Nanchang, China, was published online in JAMA Oncology. LIMITATIONS: Study limitations were single-center design and lack of placebo control. Oral mucositis assessment by a single evaluator could introduce subjectivity. The S aureus culture method might lack sensitivity, potentially underestimating colonization rates. DISCLOSURES: The trial received funding support from the Science and Technology Research Project of Education Department of Jiangxi Province, the Open Fund for Scientific Research of NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, National Natural Science Foundation of China, and 'Five-level Progressive' talent cultivation project of Jiangxi Province Key R&D Program, and Jiangxi Cancer Hospital & Institute. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
UPI
6 days ago
- UPI
Trial shows promise for new bloodborne staph infection treatment
The National Institute of Allergy and Infectious Diseases said a new treatment for bloodborne staph infections showed promise in a clinical trial. File Photo by Tamas Soki/EPA A new way to battle bloodborne staph infections could help save lives while combating the rise of antibiotic-resistant bacteria, according to new clinical trial results. Two intravenous doses of the antibiotic dalbavancin delivered seven days apart worked just as well as daily IV doses of conventional antibiotics in quelling Staphylococcus aureus bloodstream infections, researchers reported Wednesday in the Journal of the American Medical Association. "Given the small number of antimicrobial drugs available to treat Staphylococcus aureus bloodstream infections and the bacteria's growing drug resistance, establishing dalbavancin as a beneficial therapy for these severe infections gives us a vital new alternative to treat them," Dr. John Beigel said in a news release. He's acting director of microbiology and infectious diseases at the National Institute of Allergy and Infectious Diseases. NIAID sponsored and funded the trial, which involved 200 hospitalized adults with complicated staph blood infections treated at 23 medical centers in the U.S. and Canada. The patients were randomly assigned to receive either two doses of dalbavancin or daily IV antibiotics, with overall treatment lasting four to eight weeks. In all, 100 received dalbavancin and the same number had standard antibiotics. Dalbavancin is a relatively recent antibiotic discovery, approved by the U.S. Food and Drug Administration in May 2014, according to The standard antibiotics used depended on the type of staph a person had. Cefazolin or penicillin were used for regular staph, while vancomycin or daptomycin were implemented against antibiotic-resistant staph, also known as MRSA. Results showed that dalbavancin worked about as well as standard therapy, providing doctors a new option for treating a severe staph infection. "Our findings give patients and health care providers the data to support an extra choice when deciding on treatment for complicated S. aureus bacteremia," lead researcher Dr. Nicholas Turner, an assistant professor at Duke University School of Medicine in Durham, N.C., said in a news release. What's more, the dalbavancin was easier to deliver. People receiving daily antibiotics needed an implanted catheter that remained in place for the full duration of their treatment -- something that can lead to complications like blood clots and additional infections. By comparison, people receiving dalbavancin only needed a short catheter inserted twice for about an hour each time, researchers said. As a result, side effects like blood clots occurred more often in the standard treatment group compared to the dalbavancin group, researchers found. Serious side effects were about as common with dalbavancin as with standard antibiotics -- 40 cases versus 34 cases, results show. However, severe events leading to treatment discontinuation occurred in 12% of the standard treatment patients compared to 3% of those treated with dalbavancin. Researchers next plan to compare the cost-effectiveness of the two approaches. More information The Cleveland Clinic has more about staph infections. Copyright © 2025 HealthDay. All rights reserved.
Time Business News
6 days ago
- Time Business News
Hygiene Tech Meets Healing Proteins
Hospital-acquired infections can be caused by the cross-infection from surface and skin of patient, equipment, and healthcare staff. Various types of products and services are available to control hospital-acquired infections such as sterilization, cleaning & disinfection products, protective barriers, and endoscope reprocessing products. Increase in awareness regarding personal hygiene after COVID-19 is a major factor to boost the Hospital Infection Prevention and Control growth. Growth factors, proteins or peptides found in nature, are important for the control of cell actions like growth, specialization, movement, and survival. They attach to certain receptors on cell surfaces, which starts signals inside the cells that change how they act. Growth factors are needed for body functions such as development in embryos, healing wounds, fixing tissues, and immune reactions. Key Growth Drivers and Opportunities High Cases of Hospital Acquired Infections: Hospital-acquired infections (HAIs) remain a major risk to patient safety and healthcare results around the world. These infections, often caused by bacteria like Staphylococcus aureus, Clostridium difficile, and Escherichia coli, usually happen because of long hospital stays, surgeries, poor infection control, and antibiotic resistance. Those in intensive care, people with weak immune systems, and those having surgery are at risk. HAIs raise sickness and death rates; these also cause higher medical costs and longer stays in hospitals. Growing Geriatric Population: The growing geriatric population significantly contributes to the rise in hospital-acquired infections, as older adults often have weakened immune systems and require frequent medical care or hospitalization. This increases their vulnerability to infections, driving the demand for effective hospital infection prevention and control measures. As a result, healthcare facilities are investing more in disinfection, protective equipment, and sterilization solutions to ensure patient safety and reduce infection risks in aging populations. Challenges Failure of end-users to follow infection prevention rules limits how well hospital infection control works. When staff, patients, or support people don't follow hygiene rules—such as washing hands, sterilizing tools, or using safety gear— the risk of contamination and infections rises. Innovation and Expansion NAVTA & Virox Launch Free Infection Control Training for Safer Vet Care In March 2023, (National Association of Veterinary Technicians in America) NAVTA, Virox launch certificate program in infection prevention, to advance best practices in infection prevention. This program is a free online program designed to provide professionals with the knowledge needed to reduce the risk of spreading infection and create a safer workplace for their team, patients, and clients. NeoIPC Unveils Toolkit to Shield Newborns from Hospital Infections In November 2023, The NeoIPC Consortium announced the launch of a new surveillance toolkit to help neonatal intensive care units (NICUs) track and prevent hospital-acquired infections (HAIs) in high-risk newborns, including very preterm infants. This toolkit aims to standardize how infections are tracked in Newborn Intensive Care Units (NICUs) to allow for improved data gathering and assessment. It has tools, training, and reporting forms made for newborn care locations. By helping with early detection and response, this project hopes to lower infection rates and improve results for fragile newborns. Inventive Sparks, Expanding Markets The key players operating the hospital infection prevention and control market includes, 3M Company, Crosstex International, Inc., Johnson & Johnson, Belimed AG, among others. Worldwide business aims center on encouraging lasting growth, improving health and safety for the public, and boosting progress through cooperation. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
